Apoptosis

, Volume 8, Issue 3, pp 237–249 | Cite as

Apoptosis and interferons: Role of interferon-stimulated genes as mediators of apoptosis

  • M. Chawla-Sarkar
  • D. J. Lindner
  • Y.-F. Liu
  • B. R. Williams
  • G. C. Sen
  • R. H. Silverman
  • E. C. Borden
Article

Abstract

IFNs are a family of cytokines with pleiotropic biological effects mediated by scores of responsive genes. IFNs were the first human proteins to be effective in cancer therapy and were among the first recombinant DNA products to be used clinically. Both quality and quantity of life has been improved in response to IFNs in various malignancies. Despite its beneficial effects, unraveling the mechanisms of the anti-tumor effects of IFN has proven to be a complex task. IFNs may mediate anti-tumor effects either indirectly by modulating immunomodulatory and anti-angiogenic responses or by directly affecting proliferation or cellular differentiation of tumor cells. Both direct or indirect effects of IFNs result from induction of a subset of genes, called IFN stimulated genes (ISGs). In addition to the ISGs implicated in anti-viral, anti-angiogenic, immunomodulatory and cell cycle inhibitory effects, oligonucleotide microarray studies have identified ISGs with apoptotic functions. These include TNF-α related apoptosis inducing ligand (TRAIL/Apo2L), Fas/FasL, XIAP associated factor-1 (XAF-1), caspase-4, caspase-8, dsRNA activated protein kinase (PKR), 2'5'A oligoadenylate synthetase (OAS), death activating protein kinases (DAP kinase), phospholipid scramblase, galectin 9, IFN regulatory factors (IRFs), promyelocytic leukemia gene (PML) and regulators of IFN induced death (RIDs). In vitro IFN-α, IFN-β and IFN-γ induced apoptosis in multiple cell lines of varied histologies. This review will emphasize possible mechanisms and the role of ISGs involved in mediating apoptotic function of IFNs.

angiogenesis anti-tumor apoptosis interferon ISGs 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Borden EC, Williams BRG. Interferons. In: Bast RC Jr, Holland JF, Gansler TS, eds. Cancer Medicine, 5th edition, Toronto: B.C. Decker Inc 2000: 815–824.Google Scholar
  2. 2.
    Stark GR, Kerr IM, Williams BRG, Silverman RH, Schreiber RD. How cells respond to interferons. Ann Rev Biochem 1998; 67227–264.Google Scholar
  3. 3.
    Pfeffer LM, Dinarello CA, Herbermann RB, et al. Biological properties of recombinant ?-interferons: 40th anniversary of the discovery of Interferons. Cancer Res 1998; 582489–2499.Google Scholar
  4. 4.
    Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994; 2641415–1421.Google Scholar
  5. 5.
    Leaman DW, Chawla-Sarkar M, Vyas K, Ozdemir A, Borden EC. Greater potency of IFN-? compared to IFN-?2 in inducing IFN stimulated genes in melanoma: Identification of new ISGs by oligonucleotide microarray. Submitted 2002.Google Scholar
  6. 6.
    Der SD, Zhou A, Williams BRG, Silverman RH. Identification of genes differentially regulated by interferon-a, b or g using olignucleotide arrays. Proc Natl Acad Sci USA 1998; 9515623–15628.Google Scholar
  7. 7.
    de Veer MJ, Holko M, Frevel M, Walker E, Der S, Paranjpe JM, Silverman RH, Williams BR. Functional classification of interferon-stimulated genes identified using microarrays. J Leukoc Biol 2001; 69912–920.Google Scholar
  8. 8.
    Grander D, Einhorn S. Interferon and malignant disease-How does it work and why doesn't it always? Acta Oncol 1998; 37331–338.Google Scholar
  9. 9.
    Chawla-Sarkar M, Leaman DW, Borden EC. Preferential induction of apoptosis by interferon (IFN)-? compared with IFN-?2: Correlation with TRAIL/Apo2L induction in melanoma cell lines. Clin Cancer Res 2001; 71821–1831.Google Scholar
  10. 10.
    Morrison BH, Bauer JA, Kalvakolanu DV, Lindner DJ. Inositol hexakisphosphate kinase 2 mediates growth suppressive and apoptotic effects of interferon-beta in ovarian carcinoma cells. J Biol Chem 2001; 27624965–24970.Google Scholar
  11. 11.
    Chen Q, Gong B, Mahmoud-Ahmed AS, et al. Apo2L/TRAIL and Bcl2 related proteins regulate type I interferon induced apoptosis in mutiple myeloma. Blood 2001; 982183–2192.Google Scholar
  12. 12.
    Ossina NK, Cannas A, Powers VC, et al. Interferongamma modulates a p53-independent apoptotic pathway and apoptosis-related gene expression. J Biol Chem 1997; 27216351–16357.Google Scholar
  13. 13.
    Thyrell L, Erickson S, Zhivotovsky B, et al. Mechanisms of IFN-alpha induced apoptosis in malignant cells. Oncogene 2002; 211251–1262.Google Scholar
  14. 14.
    Sangfelt O, Erickson S, Castro J, Heiden T, Einhorn S, Grander D. Induction of apoptosis and inhibition of cell growth are independent responses to interferon-alpha in hematopoietic cell lines. Cell Growth Differ 1997; 8343–352.Google Scholar
  15. 15.
    Otsuki T, Yamada O, Sakaguchi H. Human myeloma cell apoptosis induced by interferon-?2. Br J Haematol 1998; 103518–529.Google Scholar
  16. 16.
    Balkwill F, Taylor-Papadinitriou J. Interferon affects both G1 and S+ G2 in cells stimulated from quiescence to growth. Nature 1978; 274798–800.Google Scholar
  17. 17.
    Kumar A, Atlad I. Interferon-? induces the expression of retinoblastoma gene product in human burkitt lymphoma Daudi cells: Role in growth regulation. Proc Natl Acad Sci USA 1992; 896599–6603.Google Scholar
  18. 18.
    Tienfenbrun N, Melamed D, Levy N. Alpha interferon suppresses the cyclin D3 and cdc25A genes, leading to reversible G0-like arrest. Mol Cell Biol 1996; 163934–3944.Google Scholar
  19. 19.
    Subramaniam PS, Cruz PE, Hobeika AC, Johnson HM. Type I interferon induction of the Cdk-inhibitor p21 WAF1 is accompanied by order G1 arrest, differentiation and apoptosis of the Daudi B-cell line. Oncogene 1998; 161885–1890.Google Scholar
  20. 20.
    Raff M. Cell suicide for beginners. Nature 1998; 39119–122.Google Scholar
  21. 21.
    Thornberry NA, Lazebnik Y. Caspases: Enemies within. Science 1998; 2811312–1316.Google Scholar
  22. 22.
    Ashkenazi A, Dixit VM. Death receptors: Signaling and modulation. Science 1998; 2811305–1308.Google Scholar
  23. 23.
    Earnshaw WC, Martins LM, Kaufmann SH. Mammalian caspases: Structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem 1999; 68383–424.Google Scholar
  24. 24.
    Balachandran S, Roberts PC, Kipperman T, et al. Alpha/beta interferons potentiate virus-induced apoptosis through activation of the FADD/Caspase-8 death signaling pathway. J Virol 2000; 741513–1523.Google Scholar
  25. 25.
    Spets H, Georgi-Hemming P, Silsajon J, Nilsson K, Jernberg-Wiklund H. Fas/Apo-1 mediated apoptosis is activated by IFN-? and IFN-? in IL-6 dependent and IL-6 independent multiple myeloma cell lines. Blood 1998; 922914–2923.Google Scholar
  26. 26.
    Selleri C, Sato T, Del Vecchio L, et al. Involvement of Fas-mediated apoptosis in the inhibitory effects of interferonalpha in chronic myelogenous leukemia. Blood 1997; 89957–964.Google Scholar
  27. 27.
    Buechner SA, Wernli M, Harr T, Hahn S, Itin P, Erb P. Regression of basal cell carcinoma by intralesional interferonalpha treatment is mediated by CD95 (Apo-1/Fas)-CD95 ligand induced suicide. J Clin Invest 1997; 1002691–2696.Google Scholar
  28. 28.
    Ahn EY, Pan G, Vickers SM, McDonald JM. IFN-gamma upregulates apoptosis-related molecules and enhances Fasmediated apoptosis in human cholangiocarcinoma. Int J Cancer 2002; 100445–451.Google Scholar
  29. 29.
    Ugurel S, Seiter S, Rappl G, Stark A, Tilgen W, Reinhold U. Heterogenous susceptibility to CD95-induced apoptosis in melanoma cells correlates with bcl-2 and bcl-x expression and is sensitive to modulation by interferon-gamma. Int J Cancer 1999; 82727–736.Google Scholar
  30. 30.
    Kayagaki N, Yamaguchi N, Nakayama M, Eto H, Okumura K, Yagita H. Type I Interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T Cells: A novel mechanism for the antitumor effects of type I IFNs. J Exp Med 1999; 1891451.Google Scholar
  31. 31.
    Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3673–682.Google Scholar
  32. 32.
    Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996; 27112687–12690.Google Scholar
  33. 33.
    Ruiz-Ruiz C, Lopez-Rivas A. Mitochondria-dependent and-independent mechanisms in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis are both regulated by interferon-gamma in human breast tumour cells. Biochem J 2002; 365825–832.Google Scholar
  34. 34.
    Leaman DW, Chawla-Sarkar M, Vyas K, et al. Identification of X-linked inhibitor of apoptosis associated factor-1 as and IFN stimulated gene that augments TRAIL/Apo2L-induced apoptosis. J Biol Chem 2002; 27728504–28511.Google Scholar
  35. 35.
    Liston P, Fong W, Kelly NL, et al. Identification of XAF1 as an antagonist of XIAP anticaspase activity. Nature Cell Biol 2001; 3128–133.Google Scholar
  36. 36.
    Deveraux QL, Takahashi R, Salvesan GS, Reed JC. X-linked IAP is a direct inhibitor of cell-death proteases. Nature 1997; 388300–304.Google Scholar
  37. 37.
    Fong WG, Liston P, Rajcan-Separovic E, St Jean M, Craig C, Korneluk RG. Expression and genetic analysis of XIAPassociated factor 1 (XAF1) in cancer cell lines. Genomics 2000; 70113–122.Google Scholar
  38. 38.
    Ruiz-Ruiz C, Munoz-Pinedo C, Lopez-Rivas A. Interferon-gamma treatment elevates caspase-8 expression and sensitizes human breast tumor cells to a death receptor-induced mitochondria-operated apoptotic program. Cancer Res, 2000; 605673–5680.Google Scholar
  39. 39.
    Kim PK, Mahidhara R, Seol DW. The role of caspase-8 in resistance to cancer chemotherapy. Drug Resist Updat 2001; 4293–296.Google Scholar
  40. 40.
    Bronner CE, Baker SM, Morrison PT, et al. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature 1994; 368258–261.Google Scholar
  41. 41.
    Morrison BH, Bauer JA, Hu J, et al. Inositol hexakisphosphate kinase 2 sensitizes ovarian carcinoma cells to multiple cancer therapeutics. Oncogene 2002; 21882–1889.Google Scholar
  42. 42.
    York JD, Odom AR, Murphy R, Ives EB, Wente SR. A phospholipase C-dependent inositol polyphosphate kinase pathway required for efficient messenger RNA export. Science 1999; 28596–100.Google Scholar
  43. 43.
    Hanakahi LA, Bartlet-Jones M, Chappell C, Pappin D, West SC. Binding of inositol phosphate to DNA-PK and stimulation of double-strand break repair. Cell 2000; 102721–729.Google Scholar
  44. 44.
    Nguyen H, Hiscott J, Pitha PM. The growing family of interferon regulatory factors. Cytokine Growth Factor Rev 1997; 8293–312.Google Scholar
  45. 45.
    Tanaka N, Ishihara M, Kitagawa M, et al. Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1. Cell 1994; 77829–839.Google Scholar
  46. 46.
    Tamura T, Ishihara M, Lamphier MS, et al. An IRF-1-dependent pathway of DNA damage-induced apoptosis in mitogen-activated T lymphocytes. Nature 1995; 376596–599.Google Scholar
  47. 47.
    Kano A, Haruyama T, Akaike T, Watanabe Y. IRF-1 is an essential mediator in IFN-gamma-induced cell cycle arrest and apoptosis of primary cultured hepatocytes. Biochem Biophys Res Commun 1999; 257672–677.Google Scholar
  48. 48.
    Heylbroeck C, Balachandran S, Servant MJ, et al. The IRF-3 transcription factor mediates Sendai virus-induced apoptosis. J Virol 2000; 743781–3792.Google Scholar
  49. 49.
    Gabriele L, Phung J, Fukumoto J, et al. 3rd Regulation of apoptosis in myeloid cells by interferon consensus sequencebinding protein. J Exp Med 1999; 190411–421.Google Scholar
  50. 50.
    Matin SF, Rackley RR, Sadhukhan PC, Kim MS, Novick AC, Bandyopadhyay SK. Impaired alpha-interferon signaling in transitional cell carcinoma: Lack of p48 expression in 5637 cells. Cancer Res 2001; 62261–2266.Google Scholar
  51. 51.
    Hovanessian AG, Brown RE, Kerr IM. Synthesis of low molecular weight inhibitor of protein synthesis with enzyme from interferon-treated cells. Nature 1977; 268537–540.Google Scholar
  52. 52.
    Meurs E, Chong K, Galabru J, et al. Molecular cloning and characterization of the double-stranded RNA-activated protein kinase induced by IFN. Cell 1990; 62379–390.Google Scholar
  53. 53.
    Williams BR. PKR; a sentinel kinase for cellular stress. Oncogene 1999; 186112–6120.Google Scholar
  54. 54.
    Sen GC. Viruses and interferons. Ann Rev Microbiol 2001; 55255–281.Google Scholar
  55. 55.
    Peters GA, Hartmann R, Qin J, Sen GC. Modular structure of PACT: Distinct domains for binding and activating PKR. Mol Cell Biol 2001; 211908–1920.Google Scholar
  56. 56.
    Tan SL, Katze MG. The emerging role of the interferon induced PKR protein kinase as an apoptotic effector: A new face of death? J IFN Cytokine Res 1999; 19543–554.Google Scholar
  57. 57.
    Der SD, Yang YL, Weissmann C, Williams BR. A double-stranded RNA-activated protein kinase-dependent pathway mediating stress-induced apoptosis. Proc Natl Acad Sci USA 1997; 943279–3283.Google Scholar
  58. 58.
    Donze O, Dostie J, Sonenberg N. Regulatable expression of the interferon induced double-stranded RNA dependent protein kinase PKR induces apoptosis and Fas receptor expression. Virology 1999; 256322–329.Google Scholar
  59. 59.
    Jagus R, Joshi B, Barber GN. PKR, apoptosis and cancer. Int J Biochem Cell Biol 1999; 31123–138.Google Scholar
  60. 60.
    Balachandran S, Kim CN, Yeh WC, Mak, TW, Bhalla K, Barber GN. Activation of the ds-RNA-dependent protein kinase, PKR induces apoptosis through FADD-mediated death signaling. EMBO J 1998; 176888–6902.Google Scholar
  61. 61.
    Justesen J, Hartmann R, Kjeldgaard NO. Gene structure and function of the 2'-5'-oligoadenylate synthetase family. Cell Mol Life Sci 2000; 571593–1612.Google Scholar
  62. 62.
    Clemens MJ, Williams BR. Inhibition of cell-free protein synthesis by pppA2'p5'A2'p5'A: A novel oligonucleotide synthesized by interferon-treated L cell extracts. Cell 1978; 3565–572.Google Scholar
  63. 63.
    Zhou A, Hassel BA, Silverman RH. Expression cloning of 2-5A-dependent RNAse: A uniquely regulated mediator of interferon action. Cell 1993; 72753–765.Google Scholar
  64. 64.
    Zhou A, Nie H, Silverman RH. Analysis and origins of the human and mouse RNase L genes: Mediators of interferon action. Mamm Genome 2000; 11989–992.Google Scholar
  65. 65.
    Dong B, Silverman RH. 2-5A-dependent RNase molecules dimerize during activation by 2-5A. J Biol Chem 1995; 2704133–4137.Google Scholar
  66. 66.
    Cole JL, Carroll SS, Kuo LC. Stoichiometry of 2',5'-oligoadenylate-induced dimerization of ribonuclease L.Asedimentation equilibrium study. J Biol Chem 1996; 2713979–3981.Google Scholar
  67. 67.
    Castelli JC, Hassel BA, Maran A, et al. The role of 2'-5' oligoadenylate-activated ribonuclease L in apoptosis. Cell Death Differ 1998; 5313–320.Google Scholar
  68. 68.
    Castelli JC, Hassel BA, Wood KA, et al. A study of the interferon antiviral mechanism: apoptosis activation by the 2-5A system. J Exp Med 1997; 186967–972.Google Scholar
  69. 69.
    Zhou A, Paranjape J, Brown TL, et al. Interferon action and apoptosis are defective in mice devoid of 2',5'-oligoadenylatedependent RNase L. EMBO J 1997; 166355–6363.Google Scholar
  70. 70.
    Zhou A, Paranjape JM, Hassel BA, et al. Impact of RNase L overexpression on viral and cellular growth and death. J Interferon Cytokine Res 1998; 18953–961.Google Scholar
  71. 71.
    Rusch L, Dong B, Silverman RH. Monitoring Activation of RNase L by 2',5'-oligoadenylates using purified recombinant enzyme and intact malignant glioma cells. Methods in Enzymology 2001; 34210–20.Google Scholar
  72. 72.
    Rusch L, Zhou A, Silverman RH. Caspase-dependent apoptosis by 2',5'-oligoadenylate activation of RNase L is enhanced by IFN-beta. J Interferon Cytokine Res 2000; 201091–1100.Google Scholar
  73. 73.
    Diaz-Guerra M, Rivas C, Esteban M. Activation of the IFN-inducible enzyme RNase L causes apoptosis of animal cells. Virology 1997; 236354–363.Google Scholar
  74. 74.
    Iordanov MS, Paranjape JM, Zhou A, et al. Activation of p38 mitogen-activated protein kinase and c-Jun NH(2)-terminal kinase by double-stranded RNA and encephalomyocarditis virus: Involvement of RNase L, protein kinase R, and alternative pathways. Mol Cell Biol 2000; 20617–627.Google Scholar
  75. 75.
    Carpten J, Nupponen N, Isaacs S, et al. Germline mutations in the ribonuclease L (RNase L) gene in hereditary prostate cancer 1 (HPC1)-linked families. Nat Genet 2002; 30181–184.Google Scholar
  76. 76.
    Rokman A, Ikonen T, Seppala EH, et al. Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer. Am J Hum Genet 2002; 701299–1304.Google Scholar
  77. 77.
    Wang L, McDonnell SK, Elkins DA, et al. Analysis of the RNASEL gene in familial and sporadic prostate cancer. Am J Hum Genet 2002; 71116–123.Google Scholar
  78. 78.
    Rennert H, Bercovich D, Hubert A, et al. A novel founder mutation in the RNASEL gene, 471delAAAG, Is associated with prostate cancer in Ashkenazi jews. Am J Hum Genet 2002; 71(4): 981–984.Google Scholar
  79. 79.
    Casey G, Neville PJ, Plummer SJ, et al. RNASEL R462Q variant increases risk of prostate cancer. Nat Genet 2002; 32(4): 581–583.Google Scholar
  80. 80.
    Ghosh A, Sarkar SN, Rowe TM, Sen GC. A specific isozyme of 2'-5' oligoadenylate synthetase is a dual function proapoptotic protein of the Bcl-2 family. J Biol Chem 2001; 27625447–25455.Google Scholar
  81. 81.
    Lavau C, Marchio A, Fagioli M, et al. The acute promyelocytic leukaemia-associatedPMLgene is induced by interferon. Oncogene 1995; 11871–876.Google Scholar
  82. 82.
    Wang ZG, Ruggero D, Ronchetti S, et al. PML is essential for multiple apoptotic pathways. Nat Genet 1998; 20266–272.Google Scholar
  83. 83.
    Saita N, Goto E, Yamamoto T, et al. Association of galactin-9 with eosinophil apoptosis. Int Arch Allergy Immunol 2002; 12842–50.Google Scholar
  84. 84.
    Kageshita T, Kashio Y, Yamauchi A, et al. Possible role of galectin-9 in cell aggregation and apoptosis of human melanoma cell lines and its clinical significance. Int J Cancer 2002; 99809–816.Google Scholar
  85. 85.
    Zhou Q, Zhao J, Al-Zoghaibi F, et al. Transcriptional control of the human plasma membrane phospholipid scramblase 1 gene is mediated by interferon-alpha. Blood 2000; 952593–2599.Google Scholar
  86. 86.
    Silverman RH, Halloum A, Zhou A, et al. Suppression of ovarian carcinoma cell growth in vivo by the interferon-inducible plasma membrane protein, phospholipid scramblase 1. Cancer Res 2002; 62397–402.Google Scholar
  87. 87.
    Zhou Q, Zhao J, Wiedmer T, Sims PJ. Normal hemostasis but defective hematopoietic response to growth factors in mice deficient in phospholipid scramblase 1. Blood 2002; 994030–4038.Google Scholar
  88. 88.
    Sun J, Nanjundan M, Pike LJ, Wiedmer T, Sims PJ. Plasma membrane phospholipid scramblase 1 is enriched in lipid rafts and interacts with the epidermal growth factor receptor. Biochemistry 2002; 416338–6345.Google Scholar
  89. 89.
    Sun J, Zhao J, Schwartz MA, Wang JY, Wiedmer T, Sims PJ. c-Abl tyrosine kinase binds and phosphorylates phospholipid scramblase 1. J Biol Chem 2001; 27628984–28990.Google Scholar
  90. 90.
    Deiss LP, Feinstein E, Berissi H, Cohen O, Kimchi A. Identification of a novel serine/threonine kinase and a novel 15-kD protein as potential mediators of the gamma interferon-induced cell death. Genes Dev 1995; 915–30.Google Scholar
  91. 91.
    Inbal B, Cohen O, Polak-Charcon S, et al. DAP kinase links the control of apoptosis to metastasis. Nature 1997; 390180–184.Google Scholar
  92. 92.
    Kleinerman ES, Kurzrock R, Wyatt D, Quesada JR, Gutterman JU, Fidler IJ. Activation or suppression of the tumoricidal properties of monocytes from cancer patients following treatment with human recombinant-interferon. Cancer Res 1986; 465401–5405.Google Scholar
  93. 93.
    Basham TY, Bourgeade MF, Creasey AA, Merigan TC. Interferon increases HLA synthesis in melanoma cells: Interferon resistant and-sensitive cell lines. Proc Natl Acad Sci USA 1982; 793265–3269.Google Scholar
  94. 94.
    Sato K, Hida S, Takayanagi H, et al. Antiviral response by natural killer cells through TRAIL gene induction by IFNalpha/beta. Eur J Immunol 2001; 313138–3146.Google Scholar
  95. 95.
    Liu S, Yu Y, Zhang M, Wang W, Cao X. The involvement of TNF-alpha-related apoptosis-inducing ligand in the enhanced cytotoxicity of IFN-beta-stimulated human dendritic cells to tumor cells. J Immunol 2001; 1665407–5415.Google Scholar
  96. 96.
    Dinney CP, Bielenberg DR, Perrotte P, et al. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. Cancer Res 1998; 58808–814.Google Scholar
  97. 97.
    Sidky YA, Borden EC. Inhibition of angiogenesis by interferons: Effects on tumor-and lymphocyte-induced vascular responses. Cancer Res 1987; 475155–5161.Google Scholar
  98. 98.
    Lindner DJ. Interferons as antiangiogenic agents. Curr Oncol Rep 2002; 4510–514.Google Scholar
  99. 99.
    Izawa JI, Sweeney P, Perrotte P, et al. Inhibition of tumori-genicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis. Clin Cancer Res 2002; 81258–1270.Google Scholar
  100. 100.
    LaCasse EC, Baird S, Korneluk RG, MacKenzie AE. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 1998; 173247.Google Scholar
  101. 101.
    Chawla-Sarkar M, Leaman DW, Jacobs BS, Borden EC. IFN-beta pretreatment sensitizes human melanoma cells to TRAIL/Apo2 ligand-induced apoptosis. J Immunol 2002; 169847–885.Google Scholar
  102. 102.
    Kumar-Sinha C, Varambally S, Sreekumar A, Chinnaiyan AM. Molecular cross-talk between the TRAIL and interferon signaling pathways. J Biol Chem 2002; 277575–585.Google Scholar
  103. 103.
    Marrack P, Kappler J, Mitchell T. Type I interferons keep activated T cells alive. J Exp Med 1999; 189521–530.Google Scholar
  104. 104.
    Xaus J, Cardo M, Valledor AF, Soler C, Lloberas J, Celada A. Interferon gamma induces the expression of p21waf-1 and arrests macrophage cell cycle, preventing induction of apoptosis. Immunity 1999; 11103–113.Google Scholar

Copyright information

© Kluwer Academic Publishers 2003

Authors and Affiliations

  • M. Chawla-Sarkar
    • 1
  • D. J. Lindner
    • 1
  • Y.-F. Liu
    • 1
  • B. R. Williams
    • 2
  • G. C. Sen
    • 3
  • R. H. Silverman
    • 2
  • E. C. Borden
    • 1
  1. 1.Center for Drug Discovery and Development, Taussig Cancer CenterCleveland Clinic FoundationCleveland
  2. 2.Department of Cancer BiologyLerner Research Institute, Cleveland Clinic FoundationCleveland
  3. 3.Department of Molecular BiologyLerner Research Institute, Cleveland Clinic FoundationCleveland

Personalised recommendations